Case study: Protecting Phase 2 obesity retention and study timelines

Adaptive retention strategy and disciplined data control in a high-visibility GLP-1 race

In obesity drug development, Phase 2 is where momentum becomes market confidence and where small execution failures can become outsized problems. Sponsors advancing differentiated GLP-1 assets are working under intense scrutiny, with evolving competitor dynamics and milestones tied to external expectations compressing decision cycles.

When a biotech partnered with Parexel to deliver two Phase 2 obesity studies evaluating an oral, daily small-molecule GLP-1 receptor agonist, the mandate was clear: maintain recruitment and retention momentum while staying database-lock ready, despite continuous change.
In a high-visibility program, operational drift is not an option.

Retention risk in a choice-rich market

Mid-study, retention became a defining risk. Even with oral dosing convenience, discontinuations can rise quickly, driven by GI adverse events, perceived lack of efficacy, and the reality that patients have options in today’s obesity landscape.

At the same time, expectations shifted around adverse event capture, query strategy, and database-lock readiness. Protocol amendments and late-cycle data additions further compressed timelines and raised the stakes.

The challenge was not simply speed. It was control under pressure.

Elevating retention to a program priority

Parexel treated retention as a program operating model, not a site issue to manage downstream.

A structured retention task force was launched, with increased investigator and site cadence and practical GI tolerability/dietary management strategies designed for rapid adoption. Engagement moved from episodic troubleshooting to sustained execution rhythm.

To reduce site burden and strengthen participant support at scale, Parexel deployed targeted enablers, including:

• Coordinator support to sustain data entry pace and retention outreach during peak enrollment
• Structured nutrition services with documented outputs supporting adherence
• Telehealth resources addressing mental health, fitness ideas, and nutrition counseling

Retention stability became a formal program objective—measured and managed at scale.

Data discipline under shifting expectations

As sponsor requirements evolved, Parexel adapted the data strategy holistically. Senior SMEs and delivery leadership were mobilized to align processes to the changing expectations while maintaining oversight and quality.

Approaching database locks, the team implemented a command-and-control cadence including daily stand-ups, objective progress dashboards, and clear, data-driven reporting so readiness stayed measurable and confidence stayed grounded.

Complexity did not disappear. It became manageable.

Execution that strengthened the partnership

Despite multiple protocol amendments, evolving expectations, and late-cycle data additions, Parexel:

• Met recruitment timelines across both Phase 2 studies
• Achieved strong participant retention despite competitive market dynamics
• Delivered database locks on schedule
• Maintained data integrity and sponsor confidence under pressure

Most importantly, disciplined execution built the trust that extended the partnership into Phase 3. 
 

Start a conversation

Return to Insights Center